Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.

Oncology - 1 Jan 2021

Tseng Jeng-Sen, Hsu Kuo-Hsuan, Zheng Zhe-Rong, Yang Tsung-Ying, Chen Kun-Chieh, Huang Yen-Hsiang, Su Kang-Yi, Yu Sung-Liang, Chang Gee-Chen

Abstract excerpt

OBJECTIVES: The characteristics and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in advanced EGFR-mutant lung adenocarcinoma patients with primary tumor resection (PTR) is not yet clear. METHODS: We enrolled advanced EGFR-mutant lung adenocarcinoma patients with EGFR-TKI as first-line therapy to access the impact of PTR on the outcomes. RESULTS: A total of 466 patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to ErbB Receptors

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 32894845
DOI: 10.1159/000509664

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.PMID 32894845Read ↗

The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study.Semantic proximity Read ↗

Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study.Semantic proximity Read ↗

EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery.Semantic proximity Read ↗

The 5-year survival outcomes analysis of EGFR-TKI or/and chemotherapy as initial adjuvant therapy for completely resected IIIA non-small cell lung cancer.Semantic proximity Read ↗

Salvage Surgery for Advanced Lung Adenocarcinoma After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment.Semantic proximity Read ↗

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.Semantic proximity Read ↗

Factors affecting outcome in resected EGFR-mutated lung cancer.Semantic proximity Read ↗

Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.Semantic proximity Read ↗

High-risk-pattern lung adenocarcinoma with epidermal growth factor receptor mutation is associated with distant metastasis risk and may benefit from adjuvant targeted therapy.Semantic proximity Read ↗

Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.Semantic proximity Read ↗

Spread through air spaces may predict early progression after salvage surgery for EGFR-mutant advanced lung adenocarcinoma treated with targeted therapySemantic proximity Read ↗

[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.